Company intelligence / Profile preview
Enanta Pharmaceuticals
- Ownership
- Public · ENTA
- Employees
- ~145
- Development stage
- Phase 2
Overview
Enanta has developed multiple antiviral drugs with a strong track record in HCV through its collaboration with AbbVie. Its current clinical focus includes RSV programs showing positive Phase 2 results for both N-inhibitor zelicapavir and L-inhibitor EDP‑323. Earlier-stage efforts target HBV, COVID‑19, and inflammatory diseases via novel small molecules. Glecaprevir-containing regimens have cured over one million HCV patients globally. Recent RSV data show significant reduction of disease severity and accelerated viral clearance in human challenge studies.
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- small molecules
- Industry
- Biotech
Drug pipeline
19 assets18 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $293.6M
- Total revenue
- $65.3M
- Enterprise value
- $159.7M
Beyond the preview
Go deeper on Enanta Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enanta Pharmaceuticals.